Comparative Pharmacology
Head-to-head clinical analysis: FEMCET versus MIDOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FEMCET versus MIDOL.
FEMCET vs MIDOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Femcet (butalbital/acetaminophen/caffeine) is a combination drug. Butalbital is a barbiturate that depresses the central nervous system by enhancing GABA-A receptor activity. Acetaminophen inhibits cyclooxygenase (COX) enzymes and modulates cannabinoid receptors. Caffeine is a nonselective adenosine receptor antagonist.
Midol is a combination product containing acetaminophen (analgesic/antipyretic via COX inhibition in CNS), caffeine (adenosine receptor antagonist), and pyrilamine (H1 antihistamine). The primary mechanism for dysmenorrhea is prostaglandin synthesis inhibition by acetaminophen.
500 mg orally every 8 hours or 650 mg orally every 6 hours; maximum 4 g/day.
Acetaminophen 500 mg, PAM Bromide 15 mg, Pyrilamine Maleate 15 mg: 2 tablets orally every 4-6 hours as needed for dysmenorrhea; maximum 10 tablets per day.
None Documented
None Documented
Clinical Note
moderateIopamidol + Metformin
"The risk or severity of adverse effects can be increased when Iopamidol is combined with Metformin."
Terminal elimination half-life: 8-12 hours (mean 10 hours). Clinically, dosing interval is every 12 hours to maintain therapeutic levels in chronic pain management.
Acetaminophen: 2-3 hours in adults; prolonged to 4-6 hours in neonates or hepatic impairment. Caffeine: 3-6 hours; prolonged in pregnancy or liver disease.
Renal: 85% (30% unchanged, 55% as glucuronide conjugate); Fecal: 15% (via biliary elimination).
Renal: >90% as acetaminophen glucuronide and sulfate conjugates; unchanged drug <5%. Biliary/fecal: <5%.
Category C
Category C
Analgesic Combination
Analgesic Combination